The Claim

Lean body mass loss accounts for approximately 28% of total weight loss in adults with obesity or type 2 diabetes treated with glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter-2 inhibitors, and this proportion is similar to that observed with diet-induced weight loss, indicating that lean body mass loss is a predictable metabolic consequence of weight reduction in this population.

Source: The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
53score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

In adults with obesity or type 2 diabetes, losing lean body mass makes up about 28% of total weight loss whether the weight loss comes from medication or diet, showing that this loss is a consistent metabolic outcome of weight reduction, not a unique side effect of the drugs.

See the scientific wording

Across both glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors, lean body mass loss accounts for approximately 28% of total weight loss in adults with obesity or type 2 diabetes, a proportion similar to that observed with diet-induced weight loss, suggesting this loss is a predictable metabolic consequence rather than a unique pathological effect.

Why this might work

When the body loses weight due to reduced calorie intake or glucose loss in urine, it needs more energy and glucose. To make glucose from scratch, it breaks down muscle protein to get amino acids. This process pulls protein out of lean tissue, causing muscle loss. The same thing happens whether calories are cut by eating less or by losing glucose in urine.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

    When people with obesity or diabetes lose weight using these two types of medications, about 28% of the weight lost comes from muscle and other lean tissue — just like when people lose weight by eating less. This means it’s a normal part of losing weight, not something weird or harmful caused by the drugs.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.